Progestin treatment for the prevention of preterm birth

Acta Obstet Gynecol Scand. 2011 Oct;90(10):1057-69. doi: 10.1111/j.1600-0412.2011.01178.x. Epub 2011 Jun 27.

Abstract

Progestin supplementation appears to be a promising approach to both preventing initiation of preterm labor and treating it once it is already established, given the role of progesterone in maintaining pregnancy, as well as support from basic and clinical research. Progesterone and 17α-hydroxyprogesterone acetate slow the process of cervical ripening, and this is the rationale for prophylactic long-term progestin supplementation mostly studied so far. However, progesterone (but not 17α-hydroxyprogesterone acetate) also inhibits myometrial activity even after the cervix has already ripened. Moreover, these effects depend greatly on the vehicle used and the route of administration. Understanding different mechanisms of action, as well as the importance of progestin formulation, vehicle and route of administration, is the key to finding the optimal progestin treatment for prevention of preterm birth.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Intravaginal
  • Cervical Ripening / drug effects
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Infant, Newborn
  • Injections, Intramuscular
  • Obstetric Labor, Premature / drug therapy
  • Obstetric Labor, Premature / prevention & control
  • Pregnancy
  • Pregnancy Outcome*
  • Premature Birth / drug therapy
  • Premature Birth / prevention & control*
  • Primary Prevention / methods
  • Progestins / administration & dosage*
  • Randomized Controlled Trials as Topic

Substances

  • Progestins